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Abstract
Background: The interest of patients in participating in randomized clinical trials involving treatments has
been widely studied, but there has been much less research on interest in preventive trials. The objective
of this study was to find out how many women would be interested in a trial involving postmenopausal
hormone therapy (PHT) and how the women's background characteristics and opinions correlated to
their interest.
Methods: The data come from recruitment questionnaires (n = 2000) sent to women in Estonia in 1998.
A random sample of women aged 45 to 64 was drawn from the Population Registry. The trial is a two-
group randomized trial comparing estrogen-progestogen therapy with placebo or no drugs. A brief
description of the study was attached to the questionnaires. Women were not told at this stage of the
recruitment which group they would be assigned to, however, they were told of the chance to receive
either hormone, placebo or no treatment.
Results: After two reminders, 1312 women (66%) responded. Eleven percent of the women approached
(17% of the respondents) were interested in joining the trial, and 8% wanted more information before
deciding. When the 225 women who stated clearly that they were interested in joining and the 553 women
who said they were not interested were compared, it was found that interested women were younger
and, adjusting for age, that more had given birth; in other respects, the sociodemographic characteristics
and health habits of the interested women were similar to those of the non-interested women. The
interested women had made more use of more health services, calcium preparations and PHT, they were
more often overweight, and more had chronic diseases and reported symptoms. Interested women's
opinions on the menopause were more negative, and they favoured PHT more than the non-interested
women.
Conclusion: Unlike the situation described in previous reports on preventive trials, in this case Estonian
women interested in participating in a PHT trial were not healthier than other women. This suggests that
trials involving PHT are more similar to treatment trials than to preventive trials. In a randomized
controlled trial, more information should be obtained from those women who decline to participate.
Published: 12 April 2005
BMC Medical Research Methodology 2005, 5:12 doi:10.1186/1471-2288-5-12
Received: 13 September 2004
Accepted: 12 April 2005
This article is available from: http://www.biomedcentral.com/1471-2288/5/12
© 2005 Hovi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
BMC Medical Research Methodology 2005, 5:12 http://www.biomedcentral.com/1471-2288/5/12Background
Randomized controlled trials (RCTs) are needed so as to
avoid bias in scientific research. There are many studies
and reviews on factors that promote or hinder interest in
participating in treatment trials – both in regard to
patients and physicians [see e.g. [1-4]]. Men, patients who
are older, less educated and from lower socioeconomic
backgrounds, non-whites, smokers, and persons lacking
adequate social support are more willing to participate in
clinical trials. Furthermore, they tend to be more severely
ill than those who do not participate. Identified obstacles
include patients' and physicians' disapproval of patients'
serving as research subjects, a lack of altruistic motives,
distrust of the medical profession, a lack of knowledge of
what is required of trial participants, and preference for a
certain treatment. Many patients do not understand the
reasons why treatments should be allocated at random,
and this is an important reason why patients choose not
to join randomized clinical trials. [5-8]. Disinterest on the
part of patients and physicians in participating in clinical
trials constitutes a threat to the generalizability of RCTs
[9].
There has been much less research on participation in tri-
als studying preventive measures (preventive trials). The
data available thus far suggest that there is a difference in
the types of people who join preventive trials and treat-
ment trials. Participants in preventive trials tend to be bet-
ter off than non-participants as regards socioeconomic
situation, health habits and health [10-14]. However,
most evaluative studies have failed to document ade-
quately the characteristics of persons who were eligible
but did not participate [1]. Less is known of physicians'
motivation as regards including or encouraging people to
participate in preventive trials [15]. Preventive drug ther-
apy, and thus trials involving such drugs, are likely to
increase in the future, and more information is needed on
who wants to take part in preventive trials. Such data are
useful in order to increase the recruitment rate as well as
to interpret trial results.
By means of a mailed questionnaire in the Estonian Post-
menopausal Hormone Therapy (EPHT)-trial, we recruited
healthy 45–64-year-old Estonian women for studying the
long-term (5-year) health effects of PHT. The trial investi-
gated the immediate effects of PHT on well-being and
symptoms, impacts on the experience of the climacteric,
on aging and partner relationships, and influences on the
use of health services. Furthermore, the trial investigated
the placebo effect and trial effect by means of the design
as well as their effect on recruitment and compliance. The
object of this paper is to report on how many women were
interested in participating in such a trial and how sociode-
mographic characteristics, health, health habits, health
services utilization and opinions regarding the meno-
pause and aging influence women's interest.
Methods
The trial is a two-group randomized trial comparing oes-
trogen-progestogen therapy to placebo or no drugs carried
out in Estonia. The participants were allocated to four ran-
dom arms forming two groups: the blind group was given
an active drug or a placebo, and the non-blind group was
given an active drug or no treatment. Women were
informed that drugs would be provided for five years. A
random sample of women aged 45 to 64 was drawn from
the Population Registry and questionnaires were sent to
the women. A brief description of the study was attached
to the questionnaire and women were invited to partici-
pate in the trial if they were found to be eligible. In the let-
ter, women were told about the sampling; that the trial
investigated the health problems of perimenopausal and
older women in Estonia, especially the long-term effect of
hormonal replacement therapy after cessation of periods;
and that the drugs would be provided for five years. In this
first letter, women were not presented with the trial design
in detail, but they were told that the women will be ran-
domly divided into groups of hormone treatment, pla-
cebo, or no tablets. Further, they were told that physician
examinations will be provided annually, and the possible
risks and benefits of PHT were explained. The study plan
had been accepted in the Committee of Medical Ethics in
Tallinn. The first 2000 women, in the sample of spring
1998, were sent a more detailed questionnaire, which pro-
vided more information on the respondents. After two
reminders, the response rate was 66% (n = 1 312).
The questions used in this article were structured, with
fixed alternatives. As regards current health, women were
asked to choose between very good, good, average, poor
or very poor; "very good" and "good" were later combined
to "good". To measure health status, women were asked if
they had or had had chronic diseases, such as cancer
(breast, uterus, ovary), myocardial infarction, cardiac fail-
ure, hypertension, stroke, thromboses, liver diseases,
renal failure, diabetes or icterus. In the case of other symp-
toms, women were given a checklist of 18 different symp-
toms or health problems and asked to choose all that they
had experienced within the past two weeks. In the case of
health habits, questions on current smoking, alcohol con-
sumption and exercise were asked. The choices for current
smoking were: no, yes every now and then, and yes daily,
how many cigarettes per day. The choices for alcohol con-
sumption were not at all, low, moderate, fairly high and
high. Exercise in leisure-time was elicited using the
choices not at all, a little, some, a lot, a large amount; "a
lot" and "a large amount" were later combined to "plenty
of exercise". Body mass index (BMI) was calculated byPage 2 of 6
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meters.
Women's opinions on the menopause were elicited using
the statements: "The menopause is a normal phase in a
woman's life, and usually it does not need treatment by a
doctor", and "A woman does not loose her femininity
during the menopause". Women's opinions concerning
PHT were elicited using the statements: "PHT effectively
prevents osteoporosis ", "PHT should be given to all mid-
dle-aged women with (menopausal) symptoms", and
"PHT should be given to most postmenopausal women".
The possible answers were: I totally agree, I agree some-
what, I don't know, I disagree somewhat, and I totally dis-
agree. In the analyses, the choices "I totally agree" and "I
agree somewhat " were later combined to "agree".
After the previous statements came the remark 'the next
questions deal with the menopause and PHT use. Those
with normal periods and who do not use PHT may stop
here'. This mistake resulted in our many missing answers
concerning PHT use (see Table 2), and the percentages in
Table 2 are given in two ways.
Open-ended questions were also used to ask women what
kind of positive and negative features they associated with
the menopause. The proportions giving positive or nega-
tive aspects are also reported in this article.
Testing the statistical significance of medians was done
using Mann-Whitney's U test. Age-adjusted odds ratios
(OR) with 95% confidence intervals (CI) were calculated
by logistic regression, using interested women as the refer-
ence group. SAS 8.0 was used in the analyses.
Results
Altogether 2000 questionnaires were sent and after two
reminders, 1312 women (66%) responded (Table 1).
Non-respondent women were somewhat older and were
Table 1: Distribution of women by their interest in participating in a randomized PHT preventive trial in Estonia and comparisons of 
the background characteristics of women according to their interest in participating. 1)
Interested Want more information Do not know Non-interested All respondents No reply
(n = 225) (n = 163) (n = 371) (n = 553) (n = 1312) (n = 688)
(% = 11) (% = 8) (% = 19) (% = 28) (% = 66) (% = 34)
Median age, years 2) 51 53 53* 56*** 54 53*
Lives in the capital, % 68 64 67 62 65 76 3)
Married or cohabiting, % 62 64 63 58 61
≥ 12 years of education, % 64 62 60 61 61
In employment, % 78 72 73 67 70
Given birth, % 92 92 89 854) 87
1) Adjusted for age
2) Statistically significant: * p < 0.05, *** p < 0.0001 compared to the "interested" group
3) Age adjusted OR 0.64 (CI 0.46 0.90), reference group "interested"
4) Age adjusted OR 2.00 (CI 1.16 3.46), reference group "interested"
Table 2: Comparison of health service utilization of women interested and not interested in participating in a randomized PHT 
preventive trial in Estonia, proportion (%) of women, and age-adjusted odds-ratios (OR).1)
Interested Non-interested OR (95% CI)1)
(n = 225) (n = 553)
% %
Physician visit in past year 76 68 1.53 (1.06–2.20)
Gynaecologist visit in past year 53 39 1.40 (1.01–1.94)
Used calcium drugs in last 2 weeks 32 23 1.49 (1.04–2.13)
Used PHT at some time 2) 26 11 2.62 (1.58–4.35)
Used PHT at some time 3) 16 8 2.05 (1.26–3.35)
1) Reference group: non-interested
2) Excluding missing values, interested n = 90 (40%), non-interested n = 143 (26%), see Methods
3) Including missing values in the denominatorPage 3 of 6
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respondents.
Of the 1312 respondents, 17% wanted to participate in
the trial. Using the whole sample of 2000 women as a
basis for calculation, 11% were interested in participating
in the trial, 42% did not want to participate,12% wanted
to receive more information before deciding, and 28%
gave no answer ('do not know'). (Table 1).
The socioeconomic background characteristics of these
four groups were very similar, but women in the "do not
know" and "non-interested" groups were older than inter-
ested women. After adjustment for age, it was found that
fewer non-interested than interested women had given
birth. When the women who had given a clearly positive
or negative answer to the question concerning their inter-
est in participating were compared, it was found that
interested women had had more contacts with the health-
care system – as measured by visits to a physician and a
gynaecologist during the previous year – than had non-
interested women. (Table 2). Interested women had also
used calcium drugs more often, and they more often
reported using PHT at some time than did non-interested
women.
Health habits, smoking, alcohol use, and exercise did not
vary by interest in participating (Table 3). In both groups,
more than half were mildly overweight, but heavy over-
weight was somewhat more prevalent in those interested.
Interested women more often had some chronic disease,
such as hypertension, cardiac failure or diabetes. (Table
3). There was no difference in regard to subjective current
health, or in the proportion of women who had experi-
enced hot flashes, but interested women more frequently
reported depression and sleeplessness.
Fewer women who were interested in participating in the
trial agreed that the menopause is a normal phase, and
more gave negative aspects of the menopause than did
non-interested women (Table 4). A more favourable opin-
ion of PHT was held by interested than by non-interested
respondents.
The "want more information" group was similar to the
group of interested women in regard to the variables stud-
ied, but they had had fewer gynaecologist appointments
in the last 12 months (40% vs. 53%). The "do not know"
group exhibited a clearly greater difference from interested
women: fewer of them had ever made use of PHT and cal-
cium drugs; they suffered less from irritability, depression,
joint pain, sleeplessness, sweating and hot flashes; they
had had fewer appointments with gynaecologists because
of menopausal symptoms; and they reported fewer both
positive and negative aspects of the menopause.
Discussion
In the case of many background characteristics, the inter-
ested and non-interested women were similar to each
other, or the differences between them were small. The
Table 3: Comparison of health habits and health of women interested and non-interested in participating in a randomized PHT 
preventive trial in Estonia, proportion (%) of women, and age-adjusted odds-ratios (OR).
Interested Non-interested OR (95% CI) 1)
(n = 225) (n = 553)
% %
Daily smoker 18 14 0.87 (0.56–1.34)
No alcohol 13 20 1.40 (0.88–2.20)
Plenty of exercise in leisure-time 25 28 1.13 (0.78–1.62)
BMI 25–29.9 2) 55 59 0.96 (0.69–1.34)
BMI ≥ 30 2) 26 21 0.68 (0.47–0.99)
Current health good 24 24 1.27 (0.87–1.86)
Some chronic disease 73 67 0.70 (0.49–1.00)
Tiredness 50 45 0.83 (0.60–1.15)
Irritability 29 23 0.80 (0.56–1.16)
Depression 26 19 0.65 (0.45–0.96)
Headache 36 32 0.96 (0.68–1.34)
Sweating 32 27 0.78 (0.55–1.11)
Hot flashes 28 22 0.74 (0.51–1.07)
Sleeplessness 26 20 0.67 (0.46–0.97)
No symptoms 2 9 4.04 (1.57–10.44)
1) Reference group: "interested"
2) kg/m2Page 4 of 6
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of health services, experience and attitude towards the
menopause. When compared to non-interested respond-
ents, interested women were younger, and they suffered
from poorer health in terms of chronic diseases, more
reported symptoms, and more visits to a physician.
Interested women had more negative experiences with the
menopause and a more positive attitude to PHT, and they
had also more often used PHT than had non-interested
women.
As in previous preventive trials, the interested women
were younger than those who were not interested [1]. But
in contrast to Britton et al. [1], who found that interested
women had a more healthy lifestyle, we did not find dif-
ferences in health habits – except with regard to over-
weight. The use of health services positively correlated
with women's willingness to join this trial. It seems that
women's contacts to health services may increase their
willingness to join a trial; or use of health services may
result from their poorer health: interested women had
more chronic diseases and more symptoms. Or women
expected some benefits from the trial. In an imaginary
trial of PHT, the advantages that the women expected
from the treatment was more important than how bene-
fits were described [16].
Interested women's negative experiences with the meno-
pause and positive attitude to PHT, as well as a positive
attitude towards PHT on the part of gynaecologists [17],
may have influenced women's interest in the PHT trial. By
contrast, a fifth of the respondents had no opinion
concerning PHT. Its use is still infrequent in Estonia, and
knowledge of PHT is likely to have been scant.
A limitation for generalizing the study results may result
from our particular trial design and target group. How-
ever, the trial design of blind and non-blind groups was
not presented in the invitation letter. Women were not
told at this stage of the recruitment which group they
would be assigned to, however, they were told of the
chance to receive either hormone, placebo or no treat-
ment. This trial concerned only mid-aged women, and
different factors may influence men, or young and old
people. The instruction to stop filling in the questionnaire
if the women had regular menstruation and no use for
hormone therapy resulted in mainly postmenopausal
women being included in this report; PHT use in Estonia
was low at the time of the questionnaire.
When one is recruiting participants for a randomized con-
trolled trial, more information should be obtained from
those who do not enter the trial. Ellenberg [18] argues that
information involving the selection process should be
obtained at each stage of selection, beginning with the
screening of potential participants and proceeding to the
final enrolment of those who agree to take part. This proc-
ess may establish some basis for judging limits when one
is generalizing results of an intervention trial. In the
present population-based study, the characteristics of per-
sons who did not return the questionnaire remain largely
unknown. We know that they were somewhat older and
Table 4: Comparison of opinions on aging and attitudes to PHT of women interested and non-interested in participating in a 
randomized PHT preventive trial in Estonia, proportion (%) of women, and age-adjusted odds-ratios (OR).1)
Interested Non-interested OR (95% CI) 2)
(n = 225) (n = 553)
% %
Menopause is a normal phase 46 56 0.68 (0.50–0.94)
Women do not loose femininity in 
menopause
52 51 1.01 (0.73–1.39)
PHT prevents osteoporosis 27 9 4.27 (2.75–6.64)
PHT should be given to all women 
with symptoms
32 12 3.20 (2.16–4.74)
PHT should be given to all 
postmenopausal women
17 3 5.88 (3.18–10.88)
Gave positive aspects of 
menopause
20 17 1.38 (0.92–2.08)
Gave negative aspects of 
menopause
39 28 1.82 (1.30–2.57)
1) Missing values excluded from the denominator. The proportion of missing values varied from 17 to 21% in the "interested" group, and from 23 
to 26% in the "non-interested" group.
2) Reference group: "non-interested"Page 5 of 6
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who were interested in joining the trial. Only 52% of peo-
ple living in the capital have Estonian as their home lan-
guage, and language problems in this area may explain the
lower response rate to our Estonian-language
questionnaires.
This preventive randomized controlled trial differed from
previous preventive trials in that interested women had
more chronic diseases and symptoms. In this respect they
were more similar to the participants of treatment trials, in
which interested persons tend to be sicker rather than
more interested. Possibly some women did not regard our
trial as a preventive trial but wished for better care or
treatment than they would receive outside the trial – as is
the case in treatment trials [3]
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